Trends of thrombo-inflammation biomarkers after Tocilizumab predict treatment failure better than scores in patients with severe SARS-CoV2 related respiratory failure.
作者信息
Masotti Luca, Cioni Elisa, Grifoni Elisa, Cei Francesco, Tarquini Roberto
机构信息
Internal Medicine II, San Giuseppe Hospital, Empoli, Italy.
Internal Medicine II, San Giuseppe Hospital, Empoli, Italy.
出版信息
Eur J Intern Med. 2022 Sep;103:111-112. doi: 10.1016/j.ejim.2022.06.004. Epub 2022 Jun 6.
Abstract
摘要
相似文献
1
Trends of thrombo-inflammation biomarkers after Tocilizumab predict treatment failure better than scores in patients with severe SARS-CoV2 related respiratory failure.托珠单抗治疗后血栓炎症生物标志物的变化趋势比严重SARS-CoV2相关呼吸衰竭患者的评分更能预测治疗失败。
Eur J Intern Med. 2022 Sep;103:111-112. doi: 10.1016/j.ejim.2022.06.004. Epub 2022 Jun 6.
2
Tocilizumab in COVID-19: The Cerrahpaşa-PREDICT score.托珠单抗治疗 COVID-19：Cerrahpaşa-PREDICT 评分。
J Infect Chemother. 2021 Sep;27(9):1329-1335. doi: 10.1016/j.jiac.2021.05.007. Epub 2021 May 12.
3
Tocilizumab: From Rheumatic Diseases to COVID-19.托珠单抗：从风湿性疾病到 COVID-19。
Curr Pharm Des. 2021;27(13):1597-1607. doi: 10.2174/1381612827666210311141512.
4
Predictors of poor outcome in tocilizumab treated patients with Sars-CoV-2 related severe respiratory failure: A multicentre real world study.托珠单抗治疗 SARS-CoV-2 相关严重呼吸衰竭患者预后不良的预测因素：一项多中心真实世界研究。
Int Immunopharmacol. 2022 Jun;107:108709. doi: 10.1016/j.intimp.2022.108709. Epub 2022 Mar 18.
5
Tocilizumab in patients infected by SARS-CoV2.托珠单抗用于感染严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的患者。
Med Clin (Barc). 2021 Apr 23;156(8):402-406. doi: 10.1016/j.medcli.2020.12.003. Epub 2021 Jan 28.
6
A prospective, randomised, double blind placebo-controlled trial to evaluate the efficacy and safety of tocilizumab in patients with severe COVID-19 pneumonia (TOC-COVID): A structured summary of a study protocol for a randomised controlled trial.一项旨在评估托珠单抗治疗重症 COVID-19 肺炎患者的疗效和安全性的前瞻性、随机、双盲、安慰剂对照试验（TOC-COVID）：一项随机对照试验研究方案的结构化总结。
Trials. 2020 Jun 3;21(1):470. doi: 10.1186/s13063-020-04447-3.
7
Reply: Low-Dose Tocilizumab With High-Dose Corticosteroids in Patients Hospitalized for COVID-19 Hypoxic Respiratory Failure Improves Mortality Without Increased Infection Risk.回复：对于因 COVID-19 低氧性呼吸衰竭住院的患者，低剂量托珠单抗联合高剂量皮质类固醇可改善死亡率且不增加感染风险。
Ann Pharmacother. 2022 Apr;56(4):507-508. doi: 10.1177/10600280211036047. Epub 2021 Jul 30.
8
Comment: Low-Dose Tocilizumab With High-Dose Corticosteroids in Patients Hospitalized for COVID-19 Hypoxic Respiratory Failure Improves Mortality Without Increased Infection Risk.评论：对于因COVID-19低氧性呼吸衰竭住院的患者，低剂量托珠单抗联合高剂量皮质类固醇可改善死亡率，且不会增加感染风险。
Ann Pharmacother. 2022 Apr;56(4):505-506. doi: 10.1177/10600280211036040. Epub 2021 Jul 30.
9
Association of injection Tocilizumab and inflammatory markers in COVID19.COVID19 中注射托珠单抗与炎症标志物的关系。
J Assoc Physicians India. 2022 Apr;70(4):11-12.
10
Early use of tocilizumab in the prevention of adult respiratory failure in SARS-CoV-2 infections and the utilization of interleukin-6 levels in the management.早期使用托珠单抗预防 SARS-CoV-2 感染所致成人呼吸衰竭及白细胞介素-6 水平在管理中的应用。
J Med Virol. 2021 Jan;93(1):491-498. doi: 10.1002/jmv.26288. Epub 2020 Jul 15.
本文引用的文献
1
Tocilizumab in severe COVID-19: A promise fulfilled.托珠单抗治疗重症新型冠状病毒肺炎：承诺兑现。
Eur J Intern Med. 2022 Jan;95:38-39. doi: 10.1016/j.ejim.2021.11.015. Epub 2021 Nov 22.
2
Efficacy and safety of tocilizumab in hospitalized COVID-19 patients: A systematic review and meta-analysis.托珠单抗治疗住院COVID-19患者的疗效和安全性：一项系统评价和荟萃分析。
J Infect. 2022 Mar;84(3):418-467. doi: 10.1016/j.jinf.2021.11.013. Epub 2021 Nov 20.
3
Laboratory parameters predicting mortality of adult in-patients with COVID-19 associated cytokine release syndrome treated with high-dose tocilizumab.预测接受大剂量托珠单抗治疗的COVID-19相关细胞因子释放综合征成年住院患者死亡率的实验室参数。
Acta Microbiol Immunol Hung. 2021 Aug 6. doi: 10.1556/030.2021.01526.
4
Tocilizumab in COVID-19: The Cerrahpaşa-PREDICT score.托珠单抗治疗 COVID-19：Cerrahpaşa-PREDICT 评分。
J Infect Chemother. 2021 Sep;27(9):1329-1335. doi: 10.1016/j.jiac.2021.05.007. Epub 2021 May 12.
5
Development and validation of a prediction model for tocilizumab failure in hospitalized patients with SARS-CoV-2 infection.开发和验证一种预测住院 SARS-CoV-2 感染患者托珠单抗治疗失败的模型。
PLoS One. 2021 Feb 23;16(2):e0247275. doi: 10.1371/journal.pone.0247275. eCollection 2021.
6
Interleukin-6 receptor blockade with subcutaneous tocilizumab improves coagulation activity in patients with COVID-19.白细胞介素-6 受体阻滞剂托珠单抗皮下注射可改善 COVID-19 患者的凝血活性。
Eur J Intern Med. 2021 Jan;83:34-38. doi: 10.1016/j.ejim.2020.10.020. Epub 2020 Nov 3.
Zotero 插件